ESMO: European Society for Medical Oncology

The latest news from ESMO

  1. ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being within the Oncology Workforce

    The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open

  2. Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity in Patients with Previously Treated ES-SCLC

    Findings from extended follow-up of the DeLLphi-300 study

  3. FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations

    Evidence for efficacy is based on the results from the MARIPOSA study

  4. Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe

    According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers.

  5. Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with Detectable ctDNA

    Findings from the ProBio study